Us Edaravone Injection Market Size By Applications, By Type, By End-User, By Deployment & By Technology 2032
Edaravone Injection Market was valued at USD 0.48 Billion in 2022 and is projected to reach USD 0.83 Billion by 2030, growing at a CAGR of 7.0% from 2024 to 2030.
US Edaravone Injection Market: A Comprehensive Overview
The US Edaravone Injection market has witnessed significant developments, particularly in the treatment of amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and atrophy. The introduction of Edaravone injections has provided a new avenue for managing this debilitating condition.
In May 2017, the U.S. Food and Drug Administration (FDA) approved Edaravone, marketed as RADICAVA®, for ALS treatment. This approval was based on clinical trials demonstrating its efficacy in slowing the progression of ALS symptoms. The initial administration method was through intravenous (IV) infusion, requiring patients to visit healthcare facilities regularly.
Recognizing the need for more convenient treatment options, Mitsubishi Tanabe Pharma America introduced an oral formulation, RADICAVA ORS®, approved by the FDA in May 2022. This innovation allows patients to take the medication orally, reducing the burden of frequent hospital visits. By 2024, over 16,000 individuals in the U.S. had been treated with RADICAVA formulations, accounting for more than 2 million therapy days.
The market dynamics shifted further with the entry of generic formulations. In May 2024, Gland Pharma received FDA approval for its generic Edaravone injection in 30 mg/100 ml and 60 mg/100 ml single-dose bags. This approval is significant as it offers a more affordable alternative to existing treatments, potentially increasing accessibility for patients. The company plans to launch the product through its marketing partner within the fiscal year 2025.
Similarly, Zydus Lifesciences obtained tentative FDA approval in March 2024 for its Edaravone Injection, 30 mg/100 ml single-dose vial. The drug is set to be manufactured at their facility in Jarod, near Vadodara, India. These developments indicate a growing interest among pharmaceutical companies to invest in ALS treatments, likely due to the increasing prevalence of the disease and the demand for effective therapies.
From a personal perspective, witnessing the evolution of the Edaravone market is encouraging. The availability of multiple formulations and the introduction of generics not only provide patients with more options but also foster competitive pricing, which can alleviate the financial burden associated with long-term treatments. Engaging with ALS patients and healthcare providers has highlighted the positive impact these advancements have on the quality of life, offering hope in the face of a challenging diagnosis.
In conclusion, the US Edaravone Injection market is evolving rapidly, driven by pharmaceutical innovations and a commitment to improving patient outcomes. As more companies enter the market and new formulations are developed, patients with ALS can look forward to more accessible and effective treatment options in the near future.
Get an In-Depth Research Analysis of the Global Edaravone Injection Market Size And Forecast [2025-2032]
Mitsubishi Tanabe Pharma
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Edaravone Injection Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Edaravone Injection Market
Conventional Edaravone Injection
Micronized Edaravone Injection
Reconstituted Edaravone Injection
Treatment of Acute Ischemic Stroke
Neurodegenerative Diseases
Oxidative Stress Diseases
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Syringes
Vials
Pouches
Hospitals
Specialty Clinics
Home Healthcare Settings
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Edaravone Injection Market Research Analysis
1. Introduction of the Global Edaravone Injection Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Edaravone Injection Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Edaravone Injection Market, By Type
6. Global Edaravone Injection Market, By Application
7. Global Edaravone Injection Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Edaravone Injection Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/